<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004772</url>
  </required_header>
  <id_info>
    <org_study_id>199/11794</org_study_id>
    <secondary_id>OSU-92H0250</secondary_id>
    <nct_id>NCT00004772</nct_id>
  </id_info>
  <brief_title>Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Compare the response of previously untreated patients with chronic inflammatory&#xD;
      demyelinating polyneuropathy to intravenous immune globulin vs. placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is a randomized, double-blind study. The first group receives&#xD;
      intravenous immune globulin (IVIG) on days 1, 2, and 21; the second group receives an&#xD;
      intravenous placebo on the same schedule.&#xD;
&#xD;
      Patients in either group may receive IVIG (same dosage as first group) after day 42.&#xD;
&#xD;
      Concurrent steroids and other immune globulin preparations are prohibited.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1992</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>90</enrollment>
  <condition>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immune globulin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics-- Chronic inflammatory demyelinating polyneuropathy (CIDP), i.e.:&#xD;
        Progressive or relapsing motor and sensory dysfunction of more than 1 limb over at least 2&#xD;
        months Hypo- or areflexia of at least 2 limbs No myelopathy No central demyelination No&#xD;
        drug or toxic exposure known to cause peripheral neuropathy --Prior/Concurrent Therapy-- No&#xD;
        prior corticosteroids or other immunomodulators for CIDP No prior plasmapheresis At least&#xD;
        30 days since participation in other investigational study At least 6 months since the&#xD;
        following: Cyclophosphamide Intravenous immune globulin Cyclosporine Interferon alfa&#xD;
        Azathioprine Corticosteroids Orthoclone Tacrolimus --Patient Characteristics-- Hepatic: No&#xD;
        hepatitis Renal: Not specified Neurologic: Cerebrospinal fluid (CSF) protein greater than&#xD;
        50 mg/dL CSF cell count less than 10 CSF VDRL negative 3 of the following motor&#xD;
        abnormalities by electrophysiology: Reduced conduction velocity in 2 or more motor nerves&#xD;
        Less than 80% of normal if amplitude greater than 80% of normal Less than 70% of normal if&#xD;
        amplitude less than 80% of normal Conduction block or abnormal temporal dispersion in 1&#xD;
        motor nerve No ulnar or peroneal nerve entrapment Prolonged distal latency in 2 or more&#xD;
        nerves Greater than 125% of normal if amplitude greater than 80% of normal Greater than&#xD;
        150% of normal if amplitude less than 80% of normal Absent F-waves or H response (patients&#xD;
        aged under 60) or prolonged shortest F-wave latency in 10 to 15 trials in 2 or more motor&#xD;
        nerves Other: No hypersensitivity to immune globulin No IgA deficiency No mutilation of&#xD;
        hands or feet No retinitis pigmentosa No ichthyosis No disease that would limit&#xD;
        neuromuscular assessment No endocrinopathy No connective tissue disease or vasculitis No&#xD;
        Lyme disease No malignancy No Castleman's disease No hyper- or hypothyroidism No HIV&#xD;
        infection No alcohol or drug abuse No pregnant or nursing women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerry R. Mendell</last_name>
    <role>Study Chair</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <verification_date>December 2001</verification_date>
  <study_first_submitted>February 24, 2000</study_first_submitted>
  <study_first_submitted_qc>February 24, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2000</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>demyelinating neuropathy</keyword>
  <keyword>neurologic and psychiatric disorders</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyradiculoneuropathy</mesh_term>
    <mesh_term>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

